Open AccessPhase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Author(s) -
Huiping Li,
Rongrui Liu,
Bin Shao,
Ran Ran,
Gonghua Song,
Ke Wang,
Yehui Shi,
Jihong Liu,
Weixin Hu,
Fu Chen,
Xiaoran Liu,
Gairong Zhang,
Chuanhua Zhao,
Ru Jia,
Quanren Wang,
Hope S. Rugo,
Yifan Zhang,
Guangze Li,
Jianming Xu
Publication year - 2020
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2020.03.08
Subject(s) - medicine , neutropenia , adverse effect , gastroenterology , pharmacokinetics , anemia , febrile neutropenia , confidence interval , oncology , chemotherapy
Fluzoparib (SHR3162) is a novel, potent poly(ADP-ribose) polymerases (PARP)1, 2 inhibitor that showed anti-tumor activity in xenograft models. We conducted a phase I, first-in-human, dose-escalation and expansion (D-Esc and D-Ex) trial in patients with advanced solid cancer.